VSTM2A and neoplasm: Our previous study reported that VSTM2A was an antagonist of Wnt ligands by competitively binding with membrane protein LRP6 and induced LRP6 endocytosis-dependent degradation, which in turn suppressed tumor-intrinsic Wnt/β-catenin signaling activation.8